Us Bancorp \De\ Pro Qr Therapeutics N.V. Transaction History

Us Bancorp \De\

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 01, 2022	SELL	$0.56 - $1.0 $2,848 - $5,087	-5,087 Closed	0 $0
Q1 2022 May 11, 2022	SELL	$0.9 - $8.39 $307 - $2,869	-342 Reduced 6.3%	5,087 $5,000
Q4 2021 Feb 11, 2022	BUY	$6.58 - $8.44 $11,422 - $14,651	1,736 Added 47.01%	5,429 $43,000
Q3 2021 Nov 10, 2021	BUY	$5.16 - $8.47 $10,474 - $17,194	2,030 Added 122.07%	3,693 $31,000
Q2 2021 Aug 05, 2021	BUY	$5.75 - $7.59 $9,562 - $12,622	1,663 New	1,663 $11,000
Q2 2020 Aug 07, 2020	SELL	$4.5 - $6.53 $3,681 - $5,341	-818 Closed	0 $0
Q1 2020 May 13, 2020	BUY	$5.25 - $9.9 $3,003 - $5,662	572 Added 232.52%	818 $5,000
Q4 2019 Feb 04, 2020	BUY	$5.84 - $10.51 $1,436 - $2,585	246 New	246 $2,000

17.4M

37.7K

21.3K

Ticker PRQR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 71,362,096
Market Cap $258M
Description
ProQR Therapeutics N.V., a biopharmaceutical company, engages in the discovery and development of RNA-based therapeutics for the treatment of genetic disorders. It primarily develops sepofarsen that is in phase II/III clinical trial illuminate trial for treating leber congenital amaurosis 10 disease; and ultevursen, which is in phase II/III clin...

Get notified when there are updates to the investment portfolio of Us Bancorp \De\, based on Form 13F filings with the SEC.

Stay updated on Us Bancorp \De\ with notifications on news.